Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glass, G. A.
Right arrow Articles by Bergethon, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glass, G. A.
Right arrow Articles by Bergethon, P. R.
Related Collections
Right arrow Gastrointestinal
Right arrow All Epilepsy/Seizures
Right arrow Antiepileptic drugs
NEUROLOGY 2005;64:1084-1085
© 2005 American Academy of Neurology
Brief Communications

Levetiracetam for seizures after liver transplantation

G. A. Glass, MD, J. Stankiewicz, MD, A. Mithoefer, PAC, R. Freeman, MD and P. R. Bergethon, MD

From the Departments of Neurology and Surgery, Tufts-New England Medical Center, Boston, MA.

Address correspondence and reprint requests to Dr. P.R. Bergethon, Department of Neurology, Tufts-New England Medical Center, 750 Washington Street, Box 314, Boston, MA 02111; e-mail: pbergethon{at}tufts-nemc.org

Seizures may occur after orthotopic liver transplantation. Antiepileptic drugs (AEDs) are used to treat these seizures, but the immunosuppressant regimen also may be altered. Levetiracetam is an attractive treatment because of its efficacy, lack of hepatic enzyme induction, and its rapid attainment of serum levels. Treatment with levetiracetam is efficacious, and levetiracetam-treated patients require significantly lower doses of immunosuppressant medications to achieve an equivalent antirejection effect.

Supported by a grant from UCB Pharma, Smyrna, GA. R.F. has received grants and P.R.B. has received honoraria from UCB Pharma.

Received June 17, 2004. Accepted in final form November 22, 2004.




This article has been cited by other articles:


Home page
 J Child NeurolHome page
E. Franzoni, J. Sarajlija, C. Garone, E. Malaspina, and V. Marchiani
No Kinetic Interaction Between Levetiracetam and Cyclosporine: A Case Report
J Child Neurol, April 1, 2007; 22(4): 440 - 442.
[Abstract] [PDF]

Home page
 NeurologyHome page
M. A. Lima, F. W. Drislane, and I. J. Koralnik
Seizures and their outcome in progressive multifocal leukoencephalopathy
Neurology, January 24, 2006; 66(2): 262 - 264.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.